Menu

Recent Interviews

Gary Cope, President and CEO, Barsele Minerals

Gary Cope
President and CEO | Barsele Minerals
Suite 1130 - 1055 W. Hastings Street, V6E 2E9 Vancouver (CN)

info@barseleminerals.com

+1(604) 687-8566

Interview Barsele Minerals: 'I have never seen a project with such good general conditions'.


Sébastien Plouffe, CEO and Director, Defence Therapeutics

Sébastien Plouffe
CEO and Director | Defence Therapeutics
1680 – 200 Burrard Street, V6C 3L6 Vancouver (CN)

info@defencetherapeutics.com

+1 (514) 947 2272

Interview Defence Therapeutics: Platform strategy the key to success


Humphrey Hale, CEO, Managing Geologist, Carnavale Resources Ltd.

Humphrey Hale
CEO, Managing Geologist | Carnavale Resources Ltd.
Level 2, Suite 9 389 Oxford Street, WA 6016 Mount Hawthorn (AUS)

info@carnavaleresources.com

Interview Carnavale Resources: Good cards for long-term success


27. March 2020 | 14:20 CET

Drägerwerk or Micro-X - how do investors benefit from the Corona Pandemic?

  • Healthcare
Photo credits: pixabay.com

The current Corona Pandemic is challenging people around the globe. Doctors and medical staff are under particular strain. For some time now, it has become clear that there is a lack of material and equipment to withstand a large onslaught of infected Covid-19 patients. In order to slow down the spread of the virus, the population is urged to avoid social contacts. Manufacturers of equipment and materials for the medical sector are now being flooded with orders to compensate for the shortage, and investors have the opportunity to make a financial investment.

time to read: 1 minutes by Mario Hose
ISIN: DE0005550636 , AU000000MX15


 

Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author


Federal government fills supply gap

The ventilators and medical protective equipment of Drägerwerk AG & Co. KGaA are in great demand. Two weeks ago, the company received a major order from the German government. According to the announcement, the delivery of 10,000 ventilators and protective equipment for medical personnel was agreed. The delivery will cover the next 12 months. This order is directly related to the spread of the corona virus and will be used to supply the healthcare system.

Product to combat shortages

In addition to ventilators, X-ray equipment is also needed to monitor the course of the disease in the patient's lungs. In recent years, the Australian company Micro-X Limited has developed a mobile X-ray unit that is now going into series production. The device is called the Carestream DRX Revolution Nano. The advantage is that the device can be moved, which increases the treatment comfort of the patients.

Based on the demand for the devices, the company will adapt its growth strategy and immediately initiate operational measures originally planned for a later date, Micro-X recently announced. As hospitals are now the focus of events and gaps in medical care are becoming apparent, more money is expected to flow into healthcare now and in the future.

Sales increase significantly

While Drägerwerk is a traditional billion-dollar company, at Micro-X investors can enter a growth story that is now experiencing high demand. In the past fiscal year, the company generated sales of AUD 1.9 million and was already able to announce incoming orders of AUD 2.4 million in the first quarter of 2020.

Micro-X's market capitalisation is currently AUD 31.25 million at the closing price of AUD 0.125 on the home exchange ASX. The shares of the company are not (yet) listed in Germany but information on the security is available and trading on the ASX is possible via the following details: ISIN: AU0000MX15, WKN: A2ACCY, ASX: MX1 or via the website: micro-x.com.


Author

Mario Hose

Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

17. March 2021 | 07:25 CET | by Nico Popp

Fresenius SE, Q+M Dental Group, Siemens Healthineers: Where growth meets dividends

  • Healthcare

The back-and-forth surrounding AstraZeneca's vaccine has unsettled many people. But the discussion about extremely rare side effects also shows: Vaccines and drugs are subject to strict regulations and the healthcare system is strictly regulated. While pharmaceutical companies must always expect setbacks, especially in accelerated approval procedures, the situation is different for suppliers of medical technology or consumables. We present three stocks that are benefiting from rising healthcare spending.

Read

19. January 2021 | 10:50 CET | by Nico Popp

Pfizer, Q&M Dental Group, Johnson & Johnson: Where do profiteers of the pandemic lurk?

  • Healthcare

We all know that one's health is the most important thing. But from time to time, this truism slips out of focus. The pandemic has shown that neither fame nor money can protect you from getting sick. A big step toward being healthy, however, can be made by trusting in research. The development of vaccines in record time has shown how great the potential is in science and the pharmaceutical industry. New test methods are continually coming onto the market. Three shares show that there is money to be made on the stock market from these developments.

Read

12. January 2021 | 10:28 CET | by Carsten Mainitz

CureVac, Q&M Dental, Moderna - What you didn't know - really exciting!

  • Healthcare

The World Health Organization (WHO) recorded more than 235 Covid-19 vaccine projects worldwide since January 2020, but few projects make it across the finish line. Timing is a critical factor, and early entrants will divide the huge market among themselves. These include BioNTech/Pfizer, Moderna and AstraZeneca. Still in the "test phase" is Tübingen-based CureVac, which recently entered into a sales cooperation with Bayer. Information published yesterday is positive and suggests approval of the preparation by the beginning of the second quarter of 2021 at the latest. Away from vaccine manufacturers, other Corona profiteers exist with which investors can earn handsomely. Q&M Dental from Singapore is little known. Its subsidiary is one of nine government-approved Corona testing facilities. Also, Q&M supplies Asian neighboring countries with millions of its Corona testing. We inform you about the news and potentials of known and unknown players.

Read